ProQR Therapeutics (NASDAQ:PRQR) Raised to Hold at Wall Street Zen

ProQR Therapeutics (NASDAQ:PRQR) was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “hold” rating in a research note issued on Saturday.

PRQR has been the topic of several other research reports. Citigroup reaffirmed a “market outperform” rating on shares of ProQR Therapeutics in a research report on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of ProQR Therapeutics in a report on Thursday, January 22nd. Finally, Oppenheimer began coverage on shares of ProQR Therapeutics in a research note on Thursday. They issued an “outperform” rating and a $9.00 target price for the company. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, ProQR Therapeutics has an average rating of “Moderate Buy” and an average target price of $6.80.

ProQR Therapeutics Price Performance

Shares of NASDAQ PRQR opened at $1.82 on Friday. The business has a 50-day moving average of $1.64 and a 200-day moving average of $2.07. The stock has a market capitalization of $191.48 million, a price-to-earnings ratio of -3.96 and a beta of 0.21. ProQR Therapeutics has a fifty-two week low of $1.07 and a fifty-two week high of $3.10.

ProQR Therapeutics (NASDAQ:PRQR) last released its earnings results on Thursday, March 12th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.01). ProQR Therapeutics had a negative return on equity of 61.64% and a negative net margin of 255.83%.The company had revenue of $5.50 million for the quarter, compared to the consensus estimate of $6.12 million. On average, sell-side analysts expect that ProQR Therapeutics will post -0.31 EPS for the current year.

Institutional Trading of ProQR Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Osaic Holdings Inc. lifted its position in shares of ProQR Therapeutics by 59.6% in the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 4,500 shares during the last quarter. Persistent Asset Partners Ltd increased its holdings in shares of ProQR Therapeutics by 24.5% during the 4th quarter. Persistent Asset Partners Ltd now owns 45,154 shares of the biopharmaceutical company’s stock worth $91,000 after acquiring an additional 8,874 shares during the last quarter. Diadema Partners LP raised its stake in ProQR Therapeutics by 6.2% in the 4th quarter. Diadema Partners LP now owns 167,532 shares of the biopharmaceutical company’s stock valued at $338,000 after acquiring an additional 9,838 shares during the period. Raymond James Financial Inc. lifted its holdings in ProQR Therapeutics by 15.2% during the 3rd quarter. Raymond James Financial Inc. now owns 110,270 shares of the biopharmaceutical company’s stock valued at $235,000 after purchasing an additional 14,549 shares during the last quarter. Finally, OneDigital Investment Advisors LLC lifted its holdings in ProQR Therapeutics by 23.1% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 80,000 shares of the biopharmaceutical company’s stock valued at $170,000 after purchasing an additional 15,000 shares during the last quarter. Institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.